BGP-15
SIGMA/B4813 - ≥98% (HPLC)
CAS Number: 66611-37-8
Empirical Formula (Hill Notation): C14H22N4O2· 2HCl
Molecular Weight: 351.27
MDL Number: MFCD21603901
Linear Formula: C14H22N4O2· 2HCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C14H22N4O2.2ClH/c15-14 |
| InChI key | ISGGVCWFTPTHIX-UHFFFAOYSA |
| Quality Level | 100  |
| SMILES string | Cl.Cl.NC(=N/OCC(O)CN1CCC |
| solubility | deionized water: 28 mg/mL |
| storage temp. | −20°C |
| Application: | BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins. |
| Biochem/physiol Actions: | BGP-15 is PARP inhibitor, HSP72 activator. |
| Biochem/physiol Actions: | BGP-15 is PARP inhibitor, HSP72 activator. |
| General description: | BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF). |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P264 - P270 - P301 + P310 - P405 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |